Letters to the Editor
Early Access
https://doi.org/10.4081/dr.2026.10964

Fast response in facial vitiligo monitored by non-invasive imaging during topical ruxolitinib treatment

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 27 October 2026
29
Views
9
Downloads
Vitiligo, ruxolitinib, LC-OCT

Authors

Francesca Feresin
feresinfrancesca@gmail.com
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Francesca Paola Sasso
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Alberto Di Caro
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Steven Paul Nisticò
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Giovanni Pellacani
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Annunziata Dattola
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.
Maria Elisabetta Greco
Unit of Dermatology, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Italy.

Dear Editor,

Vitiligo is a chronic autoimmune disorder affecting 0.5-1% of the population, characterized by progressive melanocyte loss and depigmented macules. Non-segmental vitiligo (NSV) is the most common subtype, typically involving the face and acral areas, with relevant psychosocial impact. Conventional therapies frequently provide delayed or incomplete responses. Recently, topical Janus kinase (JAK) inhibitors, such as ruxolitinib 1.5% cream, have shown promise in promoting repigmentation. [...]

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet 2020;396:110-20.
Pandya AG, Harris JE, Lebwohl M, et al. Addition of Narrow-Band UVB Phototherapy to Ruxolitinib Cream in Patients With Vitiligo. J Invest Dermatol 2022;142:3352-5.e4.
Rosmarin D, Passeron T, Pandya AG, et al.; TRuE-V Study Group. Two-Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med 2022;387:1445-55.
Ardigo M, Malizewsky I, Dell’anna ML, et al. Preliminary evaluation of vitiligo using in vivo reflectance confocal microscopy. J Eur Acad Dermatol Venereol 2007;21:1344-50.
Lu LY, Chen YT, Chen IL, et al. Feasibility of High-Cellular-Resolution Full-Field, Artificial-Intelligence-Assisted, Real-Time Optical Coherence Tomography in the Evaluation of Vitiligo: A Prospective Longitudinal Follow-Up Study. Bioengineering (Basel) 2024;11:196.

How to Cite



1.
Feresin F, Sasso FP, Di Caro A, Nisticò SP, Pellacani G, Dattola A, et al. Fast response in facial vitiligo monitored by non-invasive imaging during topical ruxolitinib treatment. Dermatol Reports [Internet]. 2026 Oct. 27 [cited 2026 Oct. 30];. Available from: https://journals.pagepress.net/dr/article/view/10964
Copyright (c) 2026 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.